All In Biotech

Drug Trial Radar · NCT05064345

A Study to Evaluate HB0034 in Healthy Adult Participants

A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0034 in Adult Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Dec 3, 2021

Primary completion

Sep 1, 2022

Study completion Sep 1, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose.

Conditions

  • Healthy

Interventions

  • HB0034Drug

    Recombinant Humanized Anti-IL-36R Monoclonal antibody

  • PlaceboDrug

    Palcebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with drug related adverse events (AEs)Time frame: up to 2000 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New zealand Clinical Research

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.